Bone scintigraphy

Bone scintigraphy is normally performed 2-4 hours after the injection of 550 MBq of 99mTc-labelled methylene disphosphonate (99mTc-medronate, MDP) or hydroxymethylene disphosphonate (99mTc-oxidronate, HDP). Multiple planar images or a whole-body survey of the skeleton are obtained. Skeletal scintigraphy has high sensitivity for the detection of primary and metastatic bone lesions. In the absence of reactive osteoblastic activity, the lesion itself may appear on the bone scan as a 'cold' defect.

High sensitivity (80-100%) has been reported in patients with breast carcinoma, prostatic carcinoma, bronchogenic carcinoma, gastric carcinoma, osteogenic sarcoma, cervix carcinoma, Ewing's sarcoma, head and neck carcinomas, neuroblastoma, and ovarian carcinoma. Lower sensitivity, around 75%, has been found in melanoma, small-cell lung tumours, Hodgkin's disease, renal-cell carcinoma, rhabdomyosarcoma, multiple myeloma, and bladder carcinoma.

Was this article helpful?

0 0

Post a comment